TETRAX Trademark

Trademark Overview


On Tuesday, October 19, 2021, a trademark application was filed for TETRAX with the United States Patent and Trademark Office. The USPTO has given the TETRAX trademark a serial number of 97081506. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 15, 2024. This trademark is owned by SYNERGY IMT, INC.. The TETRAX trademark is filed in the Chemical Products, Pharmaceutical Products, Treatment & Processing of Materials Services, and Computer & Software Services & Scientific Services categories with the following description:

custom manufacture of therapeutic drugs, namely, custom manufacture of cell therapies and cancer therapies; Manufacture of pharmaceuticals, pharmaceutical ingredients, vaccines and antibodies for others

pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical products for the diagnosis, prevention and treatment of cancer; Antibodies being pharmaceutical preparations for the diagnosis, treatment and prevention of cancer, immune response disorders, genetic conditions, infectious diseases and vascular diseases; Vaccines; Pharmaceutical preparations for cell therapy; Preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes

biochemicals, namely, antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules for in vitro scientific or research use

custom design and engineering of antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Providing a bioinformatics platform as a service (PAAS) featuring computer software for developing antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Custom design and engineering of antibodies; Custom design and engineering of antigens; Antibody engineering; Biochemical research and development; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development and establishment of testing specifications and procedures in the field of biotechnology; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the development of new cancer therapies; Scientific research in human and animal cell therapy; Platform as a service (PAAS) featuring computer software platforms for analysis of bioinformatic data
tetrax

General Information


Serial Number97081506
Word MarkTETRAX
Filing DateTuesday, October 19, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 18, 2023

Trademark Statements


Goods and Servicescustom manufacture of therapeutic drugs, namely, custom manufacture of cell therapies and cancer therapies; Manufacture of pharmaceuticals, pharmaceutical ingredients, vaccines and antibodies for others
Goods and Servicespharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical products for the diagnosis, prevention and treatment of cancer; Antibodies being pharmaceutical preparations for the diagnosis, treatment and prevention of cancer, immune response disorders, genetic conditions, infectious diseases and vascular diseases; Vaccines; Pharmaceutical preparations for cell therapy; Preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes
Goods and Servicesbiochemicals, namely, antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules for in vitro scientific or research use
Goods and Servicescustom design and engineering of antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Providing a bioinformatics platform as a service (PAAS) featuring computer software for developing antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Custom design and engineering of antibodies; Custom design and engineering of antigens; Antibody engineering; Biochemical research and development; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development and establishment of testing specifications and procedures in the field of biotechnology; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the development of new cancer therapies; Scientific research in human and animal cell therapy; Platform as a service (PAAS) featuring computer software platforms for analysis of bioinformatic data

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateMonday, March 13, 2023
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 13, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateMonday, March 13, 2023
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, March 13, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSYNERGY IMT, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressKirkland, WA 980337105

Party NameSYNERGY IMT, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKirkland, WA 980337105

Trademark Events


Event DateEvent Description
Tuesday, January 16, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 15, 2024ABANDONMENT - NO USE STATEMENT FILED
Tuesday, June 13, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 18, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 18, 2023PUBLISHED FOR OPPOSITION
Wednesday, March 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, March 13, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 8, 2023EXAMINER'S AMENDMENT ENTERED
Wednesday, March 8, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, March 8, 2023EXAMINERS AMENDMENT E-MAILED
Wednesday, March 8, 2023EXAMINERS AMENDMENT -WRITTEN
Monday, August 1, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 1, 2022NON-FINAL ACTION E-MAILED
Monday, August 1, 2022NON-FINAL ACTION WRITTEN
Tuesday, July 26, 2022ASSIGNED TO EXAMINER
Friday, November 5, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, October 22, 2021NEW APPLICATION ENTERED